Recombinant human lactoferrin is effective in the treatment of Helicobacter felis-infected mice.

Abstract

Recombinant human lactoferrin possesses in-vitro antibiotic and anti-inflammatory activity similar to the native form. It was tested for in-vivo activity in mice infected with the gastritis-inducing bacterium Helicobacter felis. A two-week course of treatment with lactoferrin was sufficient to partially reverse both infection-induced gastritis and the infection rate, and fully reverse gastric surface hydrophobicity changes. A comparison of lactoferrin with amoxicillin and standard triple therapy revealed no differences in infection rate. These results show that recombinant human lactoferrin is effective in a mouse model of Helicobacter infection, and support further testing of this promising agent for this application.

• Authors: E J Dial, J J Romero, D R Headon, L M Lichtenberger
• Journal: The Journal of pharmacy and pharmacology (J Pharm Pharmacol) Vol. 52 Issue 12 Pg. 1541-6 (Dec 2000) ISSN: 0022-3573 [Print] England
• PMID: 11197084 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Penicillins
• Recombinant Proteins
• Amoxicillin
• Lactoferrin

Topics

• Amoxicillin (pharmacology)
• Animals
• Body Weight (drug effects)
• Dose-Response Relationship, Drug
• Gastritis (drug therapy, etiology)
• Helicobacter (drug effects)
• Helicobacter Infections (complications, drug therapy, microbiology)
• Humans
• Lactoferrin (pharmacology)
• Mice
• Mice, Inbred C57BL
• Organ Size (drug effects)
• Penicillins (pharmacology)
• Recombinant Proteins (pharmacology)
• Stomach (drug effects, pathology)
• Time Factors